Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-01-25
2005-01-25
Raymond, Richard (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S249000, C514S252100, C514S314000, C544S353000, C544S354000, C546S167000, C546S152000, C546S153000, C546S159000
Reexamination Certificate
active
06846815
ABSTRACT:
This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor tyrosine kinase and/or Lck tyrosine kinase, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.
REFERENCES:
patent: 5409930 (1995-04-01), Spada et al.
patent: 5480883 (1996-01-01), Spada et al.
patent: 9413647 (1994-06-01), None
Chemical abstract DN 124:261073 also cited as U.S.5480883 dated Jan. 1996.
Maguire Martin P.
Myers Michael R.
Persons Paul E.
Spada Alfred P.
Aventis Pharmaceuticals Inc.
Patel Sudhaker B
Raymond Richard
Synnestvedt & Lechner LLP
LandOfFree
Quinoline and quinoxaline compounds which inhibit... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinoline and quinoxaline compounds which inhibit..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinoline and quinoxaline compounds which inhibit... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3375619